Huntington’s disease is a rare, genetic condition that results in progressive destruction of brain nerve cells. The rate at which symptoms appear can differ from person to person. For some people, motor skill changes come first, followed by depressive symptoms. Changes in mood and strange behavior are frequent early warning indicators. Functional capacities of a person are significantly impacted by Huntington’s disease, which typically causes mobility, cognitive, and psychological issues. Medications are available to help manage symptoms of Huntington’s disease. There is currently no authorized disease-modifying medication for patients with Huntington’s disease.
Major factors that drive growth of the Huntington’s disease treatment market is increase in prevalence population and rise in demand for advanced drug types for controlling symptoms associated with Huntington’s. In addition, strong drug type pipeline is a key trend in the market, which is expected to fuel growth during the forecast period.
Significant surge in patient population is one of the leading factors in the market as rise in patient lead to increase in demand for drugs. For instance, according to a research paper published by BJM Journal, there is high prevalence of HD in the UK. Such high prevalence of HD requires more ingenuity and responsiveness in its care. Thus, such high number of cases are expected to boost the Huntington’s disease treatment market growth.
In addition, surge in demand for advanced treatment such as gene therapy and stem cell therapy in the past decade drives the market growth. Furthermore, rise in R&D investments in drug discovery and development serves as an lucrative opportunity for the market growth. However, complications associated with drug development process expected to hamper the market growth.
The global Huntington’s disease treatment market is segmented on the basis of drug type, age, distribution channel, and region. On the basis of drug type, the market is categorized into approved drugs and off-label drugs. The approved drug segment is further classified into tetrabenazine and deutetrabenazine. By age, the market is divided into below 50 years and above 50 years. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
Major players profiled in the report are Annexon Biosciences, Bausch Health Companies Inc, Dr.Reddy's Laboratories Ltd, Eli Lilly And Company, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc, SOM Biotech, Sun Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., UniQure, and Vaccinex, Inc.
Major factors that drive growth of the Huntington’s disease treatment market is increase in prevalence population and rise in demand for advanced drug types for controlling symptoms associated with Huntington’s. In addition, strong drug type pipeline is a key trend in the market, which is expected to fuel growth during the forecast period.
Significant surge in patient population is one of the leading factors in the market as rise in patient lead to increase in demand for drugs. For instance, according to a research paper published by BJM Journal, there is high prevalence of HD in the UK. Such high prevalence of HD requires more ingenuity and responsiveness in its care. Thus, such high number of cases are expected to boost the Huntington’s disease treatment market growth.
In addition, surge in demand for advanced treatment such as gene therapy and stem cell therapy in the past decade drives the market growth. Furthermore, rise in R&D investments in drug discovery and development serves as an lucrative opportunity for the market growth. However, complications associated with drug development process expected to hamper the market growth.
The global Huntington’s disease treatment market is segmented on the basis of drug type, age, distribution channel, and region. On the basis of drug type, the market is categorized into approved drugs and off-label drugs. The approved drug segment is further classified into tetrabenazine and deutetrabenazine. By age, the market is divided into below 50 years and above 50 years. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
Major players profiled in the report are Annexon Biosciences, Bausch Health Companies Inc, Dr.Reddy's Laboratories Ltd, Eli Lilly And Company, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc, SOM Biotech, Sun Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., UniQure, and Vaccinex, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the huntington’s disease treatment market analysis from 2021 to 2031 to identify the prevailing huntington’s disease treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the huntington’s disease treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global huntington’s disease treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug type
- Approved drugs
- Type
- Tetrabenazine
- Deutetrabenazine
- Offlabel drugs
By Age
- Below 50 years
- Above 50 years
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- Prilenia Therapeutics
- som biotech
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Lupin
- UniQure
- Hikma Pharmaceuticals plc
- Annexon Biosciences
- Dr. Reddy’s Laboratories Ltd.
- Neurocrine Biosciences
- PTC Therapeutics
- AOP Health
- Medesis Pharma SA
- Mitochon Pharmaceuticals
- Sun Pharmaceuticals Industries Ltd.
- Vaccinex, Inc
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Approved drugs
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.2.4 Approved drugs Huntington’s Disease Treatment Market by Type
4.2.4.1 Tetrabenazine Market size and forecast, by region
4.2.4.2 Deutetrabenazine Market size and forecast, by region
4.3 Offlabel drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: HUNTINGTON’S DISEASE TREATMENT MARKET, BY AGE
5.1 Overview
5.1.1 Market size and forecast
5.2 Below 50 years
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Above 50 years
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: HUNTINGTON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 DrU.S.ore and retail pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: HUNTINGTON’S DISEASE TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug type
7.2.2.1 North America Approved drugs Huntington’s Disease Treatment Market by Type
7.2.3 North America Market size and forecast, by Age
7.2.4 North America Market size and forecast, by Distribution channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Drug type
7.2.5.1.3 Market size and forecast, by Age
7.2.5.1.4 Market size and forecast, by Distribution channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Drug type
7.2.5.2.3 Market size and forecast, by Age
7.2.5.2.4 Market size and forecast, by Distribution channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Drug type
7.2.5.3.3 Market size and forecast, by Age
7.2.5.3.4 Market size and forecast, by Distribution channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug type
7.3.2.1 Europe Approved drugs Huntington’s Disease Treatment Market by Type
7.3.3 Europe Market size and forecast, by Age
7.3.4 Europe Market size and forecast, by Distribution channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Drug type
7.3.5.1.3 Market size and forecast, by Age
7.3.5.1.4 Market size and forecast, by Distribution channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Drug type
7.3.5.2.3 Market size and forecast, by Age
7.3.5.2.4 Market size and forecast, by Distribution channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Drug type
7.3.5.3.3 Market size and forecast, by Age
7.3.5.3.4 Market size and forecast, by Distribution channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Drug type
7.3.5.4.3 Market size and forecast, by Age
7.3.5.4.4 Market size and forecast, by Distribution channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Drug type
7.3.5.5.3 Market size and forecast, by Age
7.3.5.5.4 Market size and forecast, by Distribution channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Drug type
7.3.5.6.3 Market size and forecast, by Age
7.3.5.6.4 Market size and forecast, by Distribution channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug type
7.4.2.1 Asia-Pacific Approved drugs Huntington’s Disease Treatment Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Age
7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Drug type
7.4.5.1.3 Market size and forecast, by Age
7.4.5.1.4 Market size and forecast, by Distribution channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Drug type
7.4.5.2.3 Market size and forecast, by Age
7.4.5.2.4 Market size and forecast, by Distribution channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Drug type
7.4.5.3.3 Market size and forecast, by Age
7.4.5.3.4 Market size and forecast, by Distribution channel
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Drug type
7.4.5.4.3 Market size and forecast, by Age
7.4.5.4.4 Market size and forecast, by Distribution channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Drug type
7.4.5.5.3 Market size and forecast, by Age
7.4.5.5.4 Market size and forecast, by Distribution channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Drug type
7.4.5.6.3 Market size and forecast, by Age
7.4.5.6.4 Market size and forecast, by Distribution channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug type
7.5.2.1 LAMEA Approved drugs Huntington’s Disease Treatment Market by Type
7.5.3 LAMEA Market size and forecast, by Age
7.5.4 LAMEA Market size and forecast, by Distribution channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Drug type
7.5.5.1.3 Market size and forecast, by Age
7.5.5.1.4 Market size and forecast, by Distribution channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Drug type
7.5.5.2.3 Market size and forecast, by Age
7.5.5.2.4 Market size and forecast, by Distribution channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Drug type
7.5.5.3.3 Market size and forecast, by Age
7.5.5.3.4 Market size and forecast, by Distribution channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Drug type
7.5.5.4.3 Market size and forecast, by Age
7.5.5.4.4 Market size and forecast, by Distribution channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Prilenia Therapeutics
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 som biotech
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Teva Pharmaceutical Industries Ltd.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novartis AG
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Lupin
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 UniQure
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Hikma Pharmaceuticals plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Annexon Biosciences
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Dr. Reddy’s Laboratories Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Neurocrine Biosciences
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 PTC Therapeutics
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 AOP Health
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Medesis Pharma SA
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Mitochon Pharmaceuticals
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 Sun Pharmaceuticals Industries Ltd.
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Vaccinex, Inc
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments
List of Tables
Table 1. Global Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 2. Huntington's Disease Treatment Market, for Approved Drugs, by Region, 2021-2031 (Revenue, $Million)
Table 3. Huntington's Disease Treatment Market, for Approved Drugs, by Country, 2021-2031 (Revenue, $Million)
Table 4. Global Approved Drugs Huntington's Disease Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 5. Huntington's Disease Treatment Market, for Tetrabenazine, by Region, 2021-2031 (Revenue, $Million)
Table 6. Huntington's Disease Treatment Market, for Deutetrabenazine, by Region, 2021-2031 (Revenue, $Million)
Table 7. Huntington's Disease Treatment Market, for Offlabel Drugs, by Region, 2021-2031 (Revenue, $Million)
Table 8. Huntington's Disease Treatment Market, for Offlabel Drugs, by Country, 2021-2031 (Revenue, $Million)
Table 9. Global Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 10. Huntington's Disease Treatment Market, for Below 50 Years, by Region, 2021-2031 (Revenue, $Million)
Table 11. Huntington's Disease Treatment Market, for Below 50 Years, by Country, 2021-2031 (Revenue, $Million)
Table 12. Huntington's Disease Treatment Market, for Above 50 Years, by Region, 2021-2031 (Revenue, $Million)
Table 13. Huntington's Disease Treatment Market, for Above 50 Years, by Country, 2021-2031 (Revenue, $Million)
Table 14. Global Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 15. Huntington's Disease Treatment Market, for Hospital Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 16. Huntington's Disease Treatment Market, for Hospital Pharmacies, by Country, 2021-2031 (Revenue, $Million)
Table 17. Huntington's Disease Treatment Market, for DrU.S.ore and Retail Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 18. Huntington's Disease Treatment Market, for DrU.S.ore and Retail Pharmacies, by Country, 2021-2031 (Revenue, $Million)
Table 19. Huntington's Disease Treatment Market, for Online Pharmacies, by Region, 2021-2031 (Revenue, $Million)
Table 20. Huntington's Disease Treatment Market, for Online Pharmacies, by Country, 2021-2031 (Revenue, $Million)
Table 21. Huntington's Disease Treatment Market, by Region, 2021-2031 (Revenue, $Million)
Table 22. North America Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 23. North America Approved Drugs Huntington's Disease Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 24. North America Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 25. North America Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 26. North America Huntington's Disease Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 27. U.S. Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 28. U.S. Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 29. U.S. Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 30. Canada Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 31. Canada Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 32. Canada Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 33. Mexico Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 34. Mexico Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 35. Mexico Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 36. Europe Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 37. Europe Approved Drugs Huntington's Disease Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 38. Europe Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 39. Europe Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 40. Europe Huntington's Disease Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 41. Germany Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 42. Germany Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 43. Germany Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 44. France Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 45. France Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 46. France Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 47. UK Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 48. UK Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 49. UK Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 50. Italy Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 51. Italy Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 52. Italy Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 53. Spain Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 54. Spain Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 55. Spain Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 56. Rest of Europe Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 57. Rest of Europe Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 58. Rest of Europe Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 59. Asia-Pacific Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 60. Asia-Pacific Approved Drugs Huntington's Disease Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 61. Asia-Pacific Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 62. Asia-Pacific Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 63. Asia-Pacific Huntington's Disease Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 64. Japan Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 65. Japan Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 66. Japan Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 67. China Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 68. China Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 69. China Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 70. India Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 71. India Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 72. India Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 73. Australia Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 74. Australia Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 75. Australia Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 76. South Korea Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 77. South Korea Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 78. South Korea Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 79. Rest of Asia-Pacific Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 80. Rest of Asia-Pacific Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 81. Rest of Asia-Pacific Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 82. LAMEA Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 83. LAMEA Approved Drugs Huntington's Disease Treatment Market, by Type, 2021-2031 (Revenue, $Million)
Table 84. LAMEA Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 85. LAMEA Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 86. LAMEA Huntington's Disease Treatment Market, by Country, 2021-2031 (Revenue, $Million)
Table 87. Brazil Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 88. Brazil Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 89. Brazil Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 90. Saudi Arabia Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 91. Saudi Arabia Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 92. Saudi Arabia Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 93. South Africa Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 94. South Africa Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 95. South Africa Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 96. Rest of LAMEA Huntington's Disease Treatment Market, by Drug Type, 2021-2031 (Revenue, $Million)
Table 97. Rest of LAMEA Huntington's Disease Treatment Market, by Age, 2021-2031 (Revenue, $Million)
Table 98. Rest of LAMEA Huntington's Disease Treatment Market, by Distribution Channel, 2021-2031 (Revenue, $Million)
Table 99. Prilenia Therapeutics: Company Snapshot
Table 100. Prilenia Therapeutics: Operating Segments
Table 101. Prilenia Therapeutics: Product Portfolio
Table 102. Prilenia Therapeutics: Net Sales
Table 103. Prilenia Therapeutics: Key Strategies
Table 104. Som Biotech: Company Snapshot
Table 105. Som Biotech: Operating Segments
Table 106. Som Biotech: Product Portfolio
Table 107. Som Biotech: Net Sales
Table 108. Som Biotech: Key Strategies
Table 109. Bausch Health Companies Inc.: Company Snapshot
Table 110. Bausch Health Companies Inc.: Operating Segments
Table 111. Bausch Health Companies Inc.: Product Portfolio
Table 112. Bausch Health Companies Inc.: Net Sales
Table 113. Bausch Health Companies Inc.: Key Strategies
Table 114. Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 115. Teva Pharmaceutical Industries Ltd.: Operating Segments
Table 116. Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 117. Teva Pharmaceutical Industries Ltd.: Net Sales
Table 118. Teva Pharmaceutical Industries Ltd.: Key Strategies
Table 119. Novartis AG: Company Snapshot
Table 120. Novartis AG: Operating Segments
Table 121. Novartis AG: Product Portfolio
Table 122. Novartis AG: Net Sales
Table 123. Novartis AG: Key Strategies
Table 124. Lupin: Company Snapshot
Table 125. Lupin: Operating Segments
Table 126. Lupin: Product Portfolio
Table 127. Lupin: Net Sales
Table 128. Lupin: Key Strategies
Table 129. Uniqure: Company Snapshot
Table 130. Uniqure: Operating Segments
Table 131. Uniqure: Product Portfolio
Table 132. Uniqure: Net Sales
Table 133. Uniqure: Key Strategies
Table 134. Hikma Pharmaceuticals PLC: Company Snapshot
Table 135. Hikma Pharmaceuticals PLC: Operating Segments
Table 136. Hikma Pharmaceuticals PLC: Product Portfolio
Table 137. Hikma Pharmaceuticals PLC: Net Sales
Table 138. Hikma Pharmaceuticals PLC: Key Strategies
Table 139. Annexon Biosciences: Company Snapshot
Table 140. Annexon Biosciences: Operating Segments
Table 141. Annexon Biosciences: Product Portfolio
Table 142. Annexon Biosciences: Net Sales
Table 143. Annexon Biosciences: Key Strategies
Table 144. Dr. Reddy's Laboratories Ltd.: Company Snapshot
Table 145. Dr. Reddy's Laboratories Ltd.: Operating Segments
Table 146. Dr. Reddy's Laboratories Ltd.: Product Portfolio
Table 147. Dr. Reddy's Laboratories Ltd.: Net Sales
Table 148. Dr. Reddy's Laboratories Ltd.: Key Strategies
Table 149. Neurocrine Biosciences: Company Snapshot
Table 150. Neurocrine Biosciences: Operating Segments
Table 151. Neurocrine Biosciences: Product Portfolio
Table 152. Neurocrine Biosciences: Net Sales
Table 153. Neurocrine Biosciences: Key Strategies
Table 154. Ptc Therapeutics: Company Snapshot
Table 155. Ptc Therapeutics: Operating Segments
Table 156. Ptc Therapeutics: Product Portfolio
Table 157. Ptc Therapeutics: Net Sales
Table 158. Ptc Therapeutics: Key Strategies
Table 159. Aop Health: Company Snapshot
Table 160. Aop Health: Operating Segments
Table 161. Aop Health: Product Portfolio
Table 162. Aop Health: Net Sales
Table 163. Aop Health: Key Strategies
Table 164. Medesis Pharma SA: Company Snapshot
Table 165. Medesis Pharma SA: Operating Segments
Table 166. Medesis Pharma SA: Product Portfolio
Table 167. Medesis Pharma SA: Net Sales
Table 168. Medesis Pharma SA: Key Strategies
Table 169. Mitochon Pharmaceuticals: Company Snapshot
Table 170. Mitochon Pharmaceuticals: Operating Segments
Table 171. Mitochon Pharmaceuticals: Product Portfolio
Table 172. Mitochon Pharmaceuticals: Net Sales
Table 173. Mitochon Pharmaceuticals: Key Strategies
Table 174. Sun Pharmaceuticals Industries Ltd.: Company Snapshot
Table 175. Sun Pharmaceuticals Industries Ltd.: Operating Segments
Table 176. Sun Pharmaceuticals Industries Ltd.: Product Portfolio
Table 177. Sun Pharmaceuticals Industries Ltd.: Net Sales
Table 178. Sun Pharmaceuticals Industries Ltd.: Key Strategies
Table 179. Vaccinex, Inc.: Company Snapshot
Table 180. Vaccinex, Inc.: Operating Segments
Table 181. Vaccinex, Inc.: Product Portfolio
Table 182. Vaccinex, Inc.: Net Sales
Table 183. Vaccinex, Inc.: Key Strategies
List of Figures
Figure 1. Huntington’S Disease Treatment Market Segmentation
Figure 2. Huntington’S Disease Treatment Market, 2021-2031
Figure 3. Huntington’S Disease Treatment Market, 2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Huntington’S Disease Treatment Mark.:Drivers, Restraints and Opportunities
Figure 12. Huntington’S Disease Treatment Market, By Drug Type, 2021(%)
Figure 13. Comparative Share Analysis of Approved Drugs Huntington’S Disease Treatment Market, 2021-2031(%)
Figure 14. Comparative Share Analysis of Offlabel Drugs Huntington’S Disease Treatment Market, 2021-2031(%)
Figure 15. Huntington’S Disease Treatment Market, By Age, 2021(%)
Figure 16. Comparative Share Analysis of Below 50 Years Huntington’S Disease Treatment Market, 2021-2031(%)
Figure 17. Comparative Share Analysis of Above 50 Years Huntington’S Disease Treatment Market, 2021-2031(%)
Figure 18. Huntington’S Disease Treatment Market, By Distribution Channel, 2021(%)
Figure 19. Comparative Share Analysis of Hospital Pharmacies Huntington’S Disease Treatment Market, 2021-2031(%)
Figure 20. Comparative Share Analysis of Drug Store and Retail Pharmacies Huntington’S Disease Treatment Market, 2021-2031(%)
Figure 21. Comparative Share Analysis of Online Pharmacies Huntington’S Disease Treatment Market, 2021-2031(%)
Figure 22. Huntington’S Disease Treatment Market by Region, 2021
Figure 23. U.S. Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 24. Canada Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 25. Mexico Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 26. Germany Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 27. France Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 28. Uk Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 29. Italy Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 30. Spain Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 31. Rest of Europe Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 32. Japan Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 33. China Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 34. India Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 35. Australia Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 36. South Korea Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 37. Rest of Asia-Pacific Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 38. Brazil Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 39. Saudi Arabia Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 40. South Africa Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 41. Rest of LAMEA Huntington’S Disease Treatment Market, 2021-2031($Million)
Figure 42. Top Winning Strategies, by Year
Figure 43. Top Winning Strategies, by Development
Figure 44. Top Winning Strategies, by Company
Figure 45. Product Mapping of Top 10 Players
Figure 46. Competitive Dashboard
Figure 47. Competitive Heatmap of Top 10 Key Players
Figure 48. Prilenia Therapeutic.: Net Sales ($Million)
Figure 49. Som Biotec.: Net Sales ($Million)
Figure 50. Bausch Health Companies Inc.: Net Sales ($Million)
Figure 51. Teva Pharmaceutical Industries Ltd.: Net Sales ($Million)
Figure 52. Novartis A.: Net Sales ($Million)
Figure 53. Lupi.: Net Sales ($Million)
Figure 54. Uniqur.: Net Sales ($Million)
Figure 55. Hikma Pharmaceuticals pl.: Net Sales ($Million)
Figure 56. Annexon Bioscience.: Net Sales ($Million)
Figure 57. Dr. Reddy’S Laboratories Ltd.: Net Sales ($Million)
Figure 58. Neurocrine Bioscience.: Net Sales ($Million)
Figure 59. Ptc Therapeutic.: Net Sales ($Million)
Figure 60. Aop Healt.: Net Sales ($Million)
Figure 61. Medesis Pharma S.: Net Sales ($Million)
Figure 62. Mitochon Pharmaceutical.: Net Sales ($Million)
Figure 63. Sun Pharmaceuticals Industries Ltd.: Net Sales ($Million)
Figure 64. Vaccinex, In.: Net Sales ($Million)
Executive Summary
According to the report, “Huntington’s Disease Treatment Market," the huntington’s disease treatment market was valued at $315.18 million in 2021, and is estimated to reach $707.5 million by 2031, growing at a CAGR of 8.4% from 2022 to 2031.Huntington’s disease (HD) is a hereditary and deadly disorder that causes nerve cells in the brain to break down. As a result, one's physical and mental capacities deteriorate with time. There is no cure. If it starts early in life, it is called juvenile Huntington’s disease. There is no cure, however, there are ways to cope with this disease and its symptoms. Huntington’s disease symptoms can be managed with the aid of medications. Treatments, however, are unable to stop the condition's effects on the body, mind, and behavior.
No treatments can alter the course of Huntington’s disease. However, medications can lessen some symptoms of movement and psychiatric disorders. In addition, multiple interventions can help a person adapt to changes in abilities for a certain amount of time.
Increase in prevalence of Huntington’s disease and strong product pipeline are the major Huntington's disease treatment market trends. Furthermore, innovations, development of advanced technologies, key strategies adopted by key players, and increase in awareness regarding treatment of Huntington’s disease fuels the market growth. However, post complications in drug development, which is expected to hinder the market growth. Conversely increase in R&D investments in drug discovery and development is a great opportunity for key players to invest during the Huntington's disease treatment market forecast, especially in the developing economies.
By drug type, the Huntington's disease treatment market size is segmented into approved drugs and off-label drugs. The approved drugs segment generated maximum revenue in 2021, and is expected to witness highest CAGR during the forecast period, owing to effective treatments and development of various disease-modifying therapies during forecast period.
Depending on age, the Huntington's disease treatment market size is divided into below 50 years and above 50 years. The below 50 years segment dominated the market in 2021, and is expected to witness highest CAGR during the forecast period, owing to higher incidence of disease in this age group.
Depending on distribution channel, the Huntington's disease treatment market analysis is divided into hospital pharmacies, drug store & retail pharmacies, and online pharmacies The drug store and retail pharmacies segment dominated the Huntington's disease treatment industry in 2021 as they provide advice on its offerings of over-the-counter drugs and online pharmacies is expected to witness highest CAGR during the forecast period, owing to increase in trend of online shopping and discount provided by those channels.
North America accounted for majority of the Huntington's disease treatment market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in Huntington’s disease treatment, increase in R&D investments, and presence of key and robust healthcare infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth in Huntington's disease treatment industry, owing to rise in patient population, development of healthcare infrastructure, and increase in investment projects in the region.
Key Findings of the Study
- By drug type, the approved drugs segment was the highest contributor to the market in 2021.
- By age, the below 50 years segment was the highest contributor to the market in 2021.
- Depending on distribution channel, the drug store & retail pharmacies segment was highest contributor in 2021, and is expected to continue this trend during the forecast period.
- Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Prilenia Therapeutics
- som biotech
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Lupin
- UniQure
- Hikma Pharmaceuticals plc
- Annexon Biosciences
- Dr. Reddy’s Laboratories Ltd.
- Neurocrine Biosciences
- PTC Therapeutics
- AOP Health
- Medesis Pharma SA
- Mitochon Pharmaceuticals
- Sun Pharmaceuticals Industries Ltd.
- Vaccinex, Inc
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
